No Data
No Data
Cleo Kicks off Long Path Towards FDA Approval for Ovarian Cancer Blood Tests
Still a relatively recent arrival to the bourse, Cleo Diagnostics (ASX:COV) has announced it’s commenced the FDA regulatory process to get into the US market.
Study Finds Cleo Diagnostics ' Blood Test Outperforms Clinical Benchmarks
Cleo Diagnostics (ASX:COV) said a study found that the company's ovarian cancer blood test outperformed current clinical benchmarks. The study confirmed that Cleo Diagnostics' blood test significantly
ASX Micro-cap Stock Rockets 50% on Ovarian Cancer Blood Test News
Cleo Diagnostics Ltd (ASX: COV) shares are catching the eye of investors on Wednesday.
Cleo Diagnostics Reports Its Ovarian Cancer Blood Tests Superior to Ultrasound
Nine moths after listing on the ASX, Cleo Diagnostics (ASX:COV) has made its first major biotech breakthrough.
Cleo Diagnostics Taps Lindus Health to Manage US Ovarian Cancer Clinical Trials
Ovarian cancer diagnostics company Cleo Diagnostics (ASX:COV) has tapped Lindus Health as a key partner for its US clinical trials program, according to a Thursday filing with the Australian Securitie
CLEO Taps HcFocus for US Market Entry
Ovarian cancer diagnostics company Cleo Diagnostics (ASX:COV) partnered with New York-based HcFocus for its US market access campaign, according to a Tuesday filing with the Australian Securities Exch
No Data